AGA. A. Gusak

A. A. Gusak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. A. Gusak has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Aleksander Dmitrievich Kulagin

    Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

    3 shared publications
  • Vadim V. Baykov

    RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022

    3 shared publications
  • A. N. Gavrilenko

    RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022

    2 shared publications
  • Andrey Chekalov

    RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022

    2 shared publications
  • E. V. Kondakova

    RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022

    2 shared publications
  • L. V. Stelmakh

    RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022

    2 shared publications

Latest Publications

  • Open Access

    The role of second-look biopsy in children with lymphoma

    by Andrey V. Kozlov, I. V. Kazantsev, T. V. Grishchenko, P. S. Tolkunova, I. Yu. Nikolaev, A. N. Galimov, O. I. Bogdanova, M. S. Khalipskaya, O. E. Poroshenko, A. N. Shvetsov, et al.

    Objective. Second look biopsy is the standard for confirming relapsed and refractory (R-R) lymphoma in children. However, in real-world clinical practice, R-R lymphomas sometimes may be diagnosed without second-look biopsy, relying solely on imaging data. This study is the first to comparatively analyze both approaches in children. Materials and methods. A total of 198 pediatric patients with lymphoma were included in the study. Of these, 181 children were diagnosed with R-R lymphoma after second-look biopsy (n = 111) or based solely on imaging (no second-look biopsy) (n = 70), in 17 patients with suspected R-R lymphoma, relapse was excluded after second-look biopsy. We assessed the sensitivity and negative predictive value of second-look biopsy. And compared the incidence of subsequent relapse and survival in patients with R-R lymphoma according to availability of second-look biopsy. Results. The sensitivity of second-look biopsy for confirming R-R lymphoma was 96.5%, and the negative predictive value was 76.5%. The cumulative incidence of relapse was 78.6% in children with R-R B-cell non-Hodgkin lymphoma that was previously confirmed by second-look biopsy, compared with 28.7% in patients with R-R B-cell non-Hodgkin lymphoma confirmed only by imaging (without second-look biopsy) (p = 0.003). Conclusions. Thus, these results indicate the need for second-look biopsy to confirm the diagnosis of R-R lymphoma in children, as otherwise there is a risk of overdiagnosis. However, given the suboptimal negative predictive value of second-look biopsy (76.5%), a diagnosis of relapse or primary refractoriness of lymphoma may be made in some patients based on clinical presentation and imaging data.

  • Open Access

    Efficacy and Safety of Various Treatment Regimens for Primary CNS Lymphoma: Results of a Retrospective Study Based on the Data from Nine Saint Petersburg Medical Institutions

    by Vladislav Vitalevich Markelov, Iu. S. Osipov, Yu. A. Alekseeva, S. V. Voloshin, N. A. Khasanova, S. A. Volchenkov, E. A. Ukrainchenko, E. S. Pavlyuchenko, A. Yu. Kuvshinov, Ju. N. Vinogradova, et al.

    BACKGROUND. In the Russian Federation, systematic evidence of treatment outcomes and prognosis evaluation in primary CNS lymphoma (PCNSL) patients is currently unavailable. AIM. To study the clinical and epidemiological characteristics as well as current medical practice and the first-line therapy outcomes in PCNSL patients. MATERIALS & METHODS. The study enrolled 127 adults with histologically verified PCNSL diagnosis treated from 2010 to 2024 at nine medical institutions in Saint Petersburg. Absolute majority (n = 119; 94 %) of them received various regimens of chemo- and/or immunochemotherapy (ICT). High-dose methotrexate (HD-МТХ) protocols were administered in 103 (87 %) cases, 86 % (n = 101) of PCNSL patients received rituximab. RESULTS. Response assessment was analyzed in 111 (87 %) patients. Objective response (OR) to the first-line therapy was 72 % (n = 80) including complete remissions in 38 (34 %) patients. With the follow-up of 12 months (range 0.4–151.1 months), the 2-year overall survival (OS) was 43 % (95 % confidence interval [95% CI] 34–54 %), and the 2-year event-free survival (EFS) was 30 % (95% CI 22–40 %). Prognostic factors included ECOG status and HD-МТХ administration. After ICT, 28 (38 %) patients with OR received radiation or high-dose therapy with autologous hematopoietic stem cell transplantation as consolidation treatment. Consolidation stage, irrespective of the chosen option, was associated with better rates of long-term survival: the 2-year OS was 78 % (95% CI 62–100 %), the 2-year EFS was 59 % (95% CI 41–84 %). CONCLUSION. The clinical profile of PCNSL patients, as revealed in this study, is generally consistent with published literature. Most patients received the treatment regimens in accordance with the international guidelines, however, in a part of them, suboptimal treatment was used. The best rates of long-term survival were reported in patients who achieved OR and subsequently received consolidation therapy.

  • Open Access

    Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study

    by Ya. V. Krylova, E. V. Kondakova, A. N. Gavrilenko, A. M. Chekalov, L. V. Fedorova, L. V. Stelmakh, E. V. Babenko, T. S. Shchegoleva, A. A. Gusak, V. V. Baykov, et al.

    Recent advances in the diagnosis and understanding of follicular lymphoma (FL) pathogenesis have had a significant impact on therapeutic tactics. The life expectancy of patients has increased significantly. Currently, the 5-year overall survival of FL patients achieved 90 %, and its median is approaching 20 years. However, FL remains an incurable disease with periods of remission and relapse, requiring multiple therapy courses throughout the patient’s life.The main problem is the treatment of patients with refractory/relapsed forms, especially after 3rd line of therapy, as well as with a primarily resistant course and early (in the first 2 years) relapses. Therefore, despite the indolent FL course in most patients, there remains a need for new drugs that can ensure increased treatment efficacy with minimal toxicity and simultaneously maintain a high quality of life, mainly in the presence of primary refractoriness, early progression and in later lines of therapy. In recent years, new targeted drugs have been studied – phosphoinositide 3-kinase, enhancer of zeste homolog 2 inhibitors, as well as immunological drugs (CAR-T therapy (CAR – chimeric antigen receptor) and bispecific antibodies).The article presents the possibilities of treatment for refractory/relapsed FL as 3rd and subsequent therapy lines.